Johnson & Johnson (JNJ) said Friday that its experimental drug, Tremfya, met primary and major secondary endpoints in a phase 3 study for adults with active psoriatic arthritis.
The company said Tremfya reduced signs and symptoms of active psoriatic arthritis and significantly minimized the progression of structural damage, as measured by radiographic progression at 24 weeks, compared to a placebo.
In the phase 3 study, the company said patients treated with Tremfya also showed significantly less structural damage progression, as assessed by the active psoriatic arthritis modified van der Heijde-Sharp score, which measures joint space narrowing and erosion.
The data was consistent with Tremfya's safety profile, with no new safety concerns identified, it added.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。